Drug Profile
Research programme: inflammation therapeutics - AtheroGenics
Alternative Names: MEKK inhibitors - AtheroGenicsLatest Information Update: 11 May 2009
Price :
$50
*
At a glance
- Originator National Jewish Medical and Research Center
- Developer AtheroGenics
- Class
- Mechanism of Action MAP kinase kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Inflammation